Loading
BMPR1A (Bone morphogenetic protein receptor type-1A) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gastro-oesophageal junction cancer, Colorectal cancer, Breast cancer and 1 more.
On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for BMP2, BMP4, GDF5 and GDF6.
Open Targets scores its association with cancer at 0.77 (direct and indirect evidence; datatypes literature 0.90, genetic association 0.69, somatic mutation 0.83, genetic literature 0.61). IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Stomach Adenocarcinoma.
In plain words · BMPR1A (Bone morphogenetic protein receptor type-1A) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gastro-oesophageal junction cancer, Colorectal cancer, Breast cancer and 1 more.
BMPR1A (Bone morphogenetic protein receptor type-1A) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gastro-oesophageal junction cancer, Colorectal cancer, Breast cancer and 1 more.
On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases.
No product in this corpus aims at BMPR1A yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
First described 1993. Earliest sequence paper UniProt cites for the protein: ten Dijke et al, Oncogene, 1993, "Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity". Source.
Sources: HGNC HGNC:1076 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P36894 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000107779 (association with cancer (MONDO_0004992) 0.77; per-cancer scores at or above 0.5: colorectal cancer 0.56, ovarian cancer 0.54, breast cancer 0.55 (GraphQL API, CC0)); IntOGen BMPR1A (driver in 1 cohort (Act 0, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for BMP2, BMP4, GDF5 and GDF6. Positively regulates chondrocyte differentiation through GDF5 interaction. Mediates induction of adipogenesis by GDF6. May promote the expression of HAMP, potentially via its interaction with BMP2. Location: Cell membrane; Cell surface (UniProt). Locus 10q23.2 (HGNC).
Query for this target: (TITLE:"BMPR1A" OR ABSTRACT:"BMPR1A" OR TITLE:"bone morphogenetic protein receptor type 1A" OR ABSTRACT:"bone morphogenetic protein receptor type 1A" OR TITLE:"Bone morphogenetic protein receptor type-1A" OR ABSTRACT:"Bone morphogenetic protein receptor type-1A" OR TITLE:"ALK3" OR ABSTRACT:"ALK3" OR TITLE:"CD292" OR ABSTRACT:"CD292" OR TITLE:"ACVRLK3" OR ABSTRACT:"ACVRLK3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BMPR1A, not a curated reading list.